A Phase 2 interventional study of Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg and Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg in Major Depressive Disorder, sponsored by Shire. Completed at 82 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-06-09.
Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Depressive Disorder, Major by Takeda — 1 open to participants now, 1 under way, 1 of them phase 3. Depressive Disorder, Major · Takeda.
Among the 26 studies in Depressive Disorder, Major by Takeda, this one is the 3rd largest by enrollment of the 24 interventional ones that give a count, is one of 6 that started in 2011, is one of 4 in phase 2, and was the 15th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 26 studies in Depressive Disorder, Major by Takeda is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 17 · Phase 4 3
First in 2008; this study’s year is marked. 6 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,197 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 580 across the 24 interventional studies, 73,904 across the 2 observational. Of the 25 that completed or were terminated, 24 (96%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Depressive Disorder, Major by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. The purpose of this study is to help answer the following questions:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg
Drug: Antidepressant + Placebo
Drug page: Lisdexamfetamine
Antidepressant + SPD489 oral, 10 mg, once daily for 8 weeks
Also known as: Vyvanse
Drug page: Lisdexamfetamine
Antidepressant + SPD489 oral, 30 mg, once daily for 8 weeks
Also known as: Vyvanse
Drug page: Lisdexamfetamine
Antidepressant + SPD489 oral, 50 mg, once daily for 8 weeks
Also known as: Vyvanse
Drug page: Lisdexamfetamine
Antidepressant + SPD489 oral, 70 mg, once daily for 8 weeks
Also known as: Vyvanse
oral, once daily for 8 weeks
Change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set)
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression. CHange in MADRS total score in Augmentsion Baseline to Week 16.
Time frame: Augmentation Baseline (Week 8) to Week 16
Change in Average Systolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16
Time frame: From Augmentation Baseline (Week 8) to Week 16
Change in Average Diastolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16
Time frame: From Augmentation Baseline (Week 8) to Week 16
Change in Average Pulse Rate From Augmentation Baseline (Week 8) to Week 16
Time frame: From Augmentation Baseline (Week 8) to Week 16
| Milestone | Antidepressant + Single-blind Placebo | Antidepressant + Double-blind Placebo | Antidepressant + Double-blind SPD489 10mg | Antidepressant + Double-blind SPD489 30mg | Antidepressant + Double-blind SPD489 50mg | Antidepressant + Double-blind SPD489 70mg |
|---|---|---|---|---|---|---|
| Started | 1197 | 0 | 0 | 0 | 0 | 0 |
| Completed | 855 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 342 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 40 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 16 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 74 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 83 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Met bp or pulse withdrawal criteria | 10 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 119 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Antidepressant + Single-blind Placebo | Antidepressant + Double-blind Placebo | Antidepressant + Double-blind SPD489 10mg | Antidepressant + Double-blind SPD489 30mg | Antidepressant + Double-blind SPD489 50mg | Antidepressant + Double-blind SPD489 70mg |
|---|---|---|---|---|---|---|
| Started | 463 | 78 | 78 | 78 | 78 | 80 |
| Completed | 397 | 71 | 71 | 69 | 69 | 71 |
| Not completed | 66 | 7 | 7 | 9 | 9 | 9 |
| Withdrew: Adverse event | 7 | 0 | 1 | 1 | 1 | 3 |
| Withdrew: Protocol violation | 2 | 0 | 1 | 2 | 0 | 1 |
| Withdrew: Withdrawal by subject | 17 | 4 | 3 | 4 | 2 | 2 |
| Withdrew: Lost to follow-up | 31 | 1 | 2 | 0 | 3 | 3 |
| Withdrew: Met bp or pulse withdrawal criteria | 1 | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Other | 8 | 2 | 0 | 2 | 0 | 0 |
| mmHg | Antidepressant + Double-blind Placebo | Antidepressant + Double-blind SPD489 10mg | Antidepressant + Double-blind SPD489 30mg | Antidepressant + Double-blind SPD489 50mg | Antidepressant + Double-blind SPD489 70mg |
|---|---|---|---|---|---|
| Change in Average Systolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16 | -0.2 ± 9.55 | 0.2 ± 8.58 | 0.5 ± 9.17 | 3.5 ± 7.82 | 2.6 ± 10.55 |
| mmHg | Antidepressant + Double-blind Placebo | Antidepressant + Double-blind SPD489 10mg | Antidepressant + Double-blind SPD489 30mg | Antidepressant + Double-blind SPD489 50mg | Antidepressant + Double-blind SPD489 70mg |
|---|---|---|---|---|---|
| Change in Average Diastolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16 | -0.1 ± 6.69 | -0.9 ± 6.64 | -0.1 ± 7.39 | 2.8 ± 6.58 | 1.9 ± 7.45 |
| bpm | Antidepressant + Double-blind Placebo | Antidepressant + Double-blind SPD489 10mg | Antidepressant + Double-blind SPD489 30mg | Antidepressant + Double-blind SPD489 50mg | Antidepressant + Double-blind SPD489 70mg |
|---|---|---|---|---|---|
| Change in Average Pulse Rate From Augmentation Baseline (Week 8) to Week 16 | -0.8 ± 9.95 | 0.8 ± 7.32 | 5.3 ± 8.08 | 4.0 ± 9.80 | 6.0 ± 11.25 |
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression. CHange in MADRS total score in Augmentsion Baseline to Week 16.
| units on a scale | Antidepressant + Double-blind Placebo | Antidepressant + Double-blind SPD489 10mg | Antidepressant + Double-blind SPD489 30mg | Antidepressant + Double-blind SPD489 50mg | Antidepressant + Double-blind SPD489 70mg |
|---|---|---|---|---|---|
| Change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set) | -5.4 (-7.2 to -3.5) | -6.7 (-8.6 to -4.9) | -5.3 (-7.1 to -3.4) | -6.1 (-8.1 to -4.1) | -6.3 (-8.2 to -4.4) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Antidepressant + Double-blind Placebo | — | 0/78 (0%) | 20/78 (25.6%) |
| Antidepressant + Double-blind SPD489 10mg | — | 0/77 (0%) | 30/77 (39%) |
| Antidepressant + Double-blind SPD489 30mg | — | 0/76 (0%) | 29/76 (38.2%) |
| Antidepressant + Double-blind SPD489 50mg | — | 0/78 (0%) | 36/78 (46.2%) |
| Antidepressant + Double-blind SPD489 70mg | — | 1/80 (1.3%) | 44/80 (55%) |
| Event | Antidepressant + Double-blind Placebo | Antidepressant + Double-blind SPD489 10mg | Antidepressant + Double-blind SPD489 30mg | Antidepressant + Double-blind SPD489 50mg | Antidepressant + Double-blind SPD489 70mg |
|---|---|---|---|---|---|
| CholecystitisHepatobiliary disorders | 0/78 | 0/77 | 0/76 | 0/78 | 1/80 |
| Event | Antidepressant + Double-blind Placebo | Antidepressant + Double-blind SPD489 10mg | Antidepressant + Double-blind SPD489 30mg | Antidepressant + Double-blind SPD489 50mg | Antidepressant + Double-blind SPD489 70mg |
|---|---|---|---|---|---|
| Dry mouthGastrointestinal disorders | 1/78 | 2/77 | 2/76 | 10/78 | 10/80 |
| HeadacheNervous system disorders | 10/78 | 7/77 | 5/76 | 3/78 | 8/80 |
| InsomniaPsychiatric disorders | 2/78 | 7/77 | 2/76 | 8/78 | 9/80 |
| NasopharyngitisInfections and infestations | 0/78 | 5/77 | 4/76 | 2/78 | 7/80 |
| NauseaGastrointestinal disorders | 1/78 | 5/77 | 6/76 | 1/78 | 6/80 |
| BruxismPsychiatric disorders | 1/78 | 0/77 | 1/76 | 4/78 | 6/80 |
| Decreased appetiteMetabolism and nutrition disorders | 1/78 | 4/77 | 5/76 | 5/78 | 4/80 |
| Urinary tract infectionInfections and infestations | 5/78 | 1/77 | 2/76 | 1/78 | 2/80 |
| DizzinessNervous system disorders | 2/78 | 2/77 | 2/76 | 5/78 | 1/80 |
| DiarrhoeaGastrointestinal disorders | 4/78 | 2/77 | 3/76 | 2/78 | 5/80 |
Safety Analysis Set: All subjects who took at least 1 dose of randomized investigational product and who had at least 1 post-augmentation baseline safety assessment (e.g. coming back for any visit, reporting of an adverse event \[AE\] or reporting the absence of AEs). Subjects who received only single-blind placebo were not included in this group.
| Age, Continuous(Years) | Antidepressant + Double-blind Placebo | Antidepressant + Double-blind SPD489 10mg | Antidepressant + Double-blind SPD489 30mg | Antidepressant + Double-blind SPD489 50mg | Antidepressant + Double-blind SPD489 70mg | Total |
|---|---|---|---|---|---|---|
| Mean | 43.7 ± 10.48 | 39.1 ± 11.83 | 43.4 ± 12.06 | 43.8 ± 12.4 | 41.5 ± 10.81 | 42.3 ± 11.61 |
| Age, Customized(Participants) | Antidepressant + Double-blind Placebo | Antidepressant + Double-blind SPD489 10mg | Antidepressant + Double-blind SPD489 30mg | Antidepressant + Double-blind SPD489 50mg | Antidepressant + Double-blind SPD489 70mg | Total |
|---|---|---|---|---|---|---|
| 18-55 | 69 | 70 | 62 | 60 | 71 | 332 |
| 56-65 | 9 | 7 | 14 | 18 | 9 | 57 |
| Sex: Female, Male(Participants) | Antidepressant + Double-blind Placebo | Antidepressant + Double-blind SPD489 10mg | Antidepressant + Double-blind SPD489 30mg | Antidepressant + Double-blind SPD489 50mg | Antidepressant + Double-blind SPD489 70mg | Total |
|---|---|---|---|---|---|---|
| Female | 53 | 53 | 52 | 53 | 53 | 264 |
| Male | 25 | 24 | 24 | 25 | 27 | 125 |
| Region of Enrollment(Participants) | Antidepressant + Double-blind Placebo | Antidepressant + Double-blind SPD489 10mg | Antidepressant + Double-blind SPD489 30mg | Antidepressant + Double-blind SPD489 50mg | Antidepressant + Double-blind SPD489 70mg | Total |
|---|---|---|---|---|---|---|
| ARGENTINA | 2 | 3 | 5 | 3 | 5 | 18 |
| AUSTRALIA | 0 | 0 | 0 | 2 | 3 | 5 |
| CHILE | 3 | 6 | 12 | 9 | 2 | 32 |
| UNITED KINGDOM | 1 | 0 | 0 | 0 | 0 | 1 |
| UNITED STATES | 72 | 68 | 59 | 64 | 70 | 333 |
Ran from May 2011 to primary completion in Jan 2014, 31 months.
Results were first posted in Feb 2015, 1 year 1 month after primary completion.
Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 31 months is above that.
Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine